

Cite this: *Chem. Sci.*, 2022, 13, 8371

All publication charges for this article have been paid for by the Royal Society of Chemistry

Solution structure of a thrombin binding aptamer complex with a non-planar platinum(II) compound†

Bo-Chen Zhu,^{‡a} Juan He,^{‡b} Xiao-Yu Xia,^{‡a} Jingxing Jiang,^c Wenting Liu,^{ID *a} Liu-Yi Liu,^{ID a} Bing-Bing Liang,^a Hua-Gang Yao,^b Zhuofeng Ke,^{ID *c} Wei Xia^{ID *a} and Zong-Wan Mao^{ID *a}

Thrombin Binding Aptamer (TBA) is a monomolecular well-defined two G-tetrad antiparallel G-quadruplex DNA that inhibits the activity of human α -thrombin. In this report, we synthesized a quasi-cross-shaped platinum(II) compound (L'_2L_{Pt}) with one cyclometalated and two carbene ligands. We found L'_2L_{Pt} has selective affinity to bind the TBA G-quadruplex. A fibrinogen clotting assay revealed that L'_2L_{Pt} can abrogate the inhibitory activity of TBA against thrombin. We solved the 1 : 1 L'_2L_{Pt} -TBA complex structure by NMR, which revealed a unique self-adaptive property of L'_2L_{Pt} upon binding to TBA. In the complex, a carbene ligand of L'_2L_{Pt} rotates to pair with the cyclometalated ligand to form a plane stacking over half of the TBA G-tetrad and covered by lateral TT loops. It is notable that the heavy atom Pt stays out of the G-tetrad. Meanwhile, the other carbene ligand remains relatively perpendicular and forms a hydrogen bond with a guanine to anchor the L'_2L_{Pt} position. This structure exhibits a quasi-cross-shaped Pt(II) compound bound to the G-quadruplex with an unusual "wall-mounted" binding mode. Our structures provide insights into the specific recognition of antiparallel G-quadruplex DNA by a self-adaptive Pt(II) compound and useful information for the design of selective G-quadruplex targeting non-planar molecules.

Received 27th February 2022
Accepted 29th May 2022

DOI: 10.1039/d2sc01196d

rsc.li/chemical-science

Introduction

G-quadruplexes (G4s) are four-stranded nucleic acid structures formed by guanine-rich nucleic acids.¹ Typically, four guanine bases can self-assemble through a cyclic array of Hoogsteen hydrogen bonds to form a G-quartet with a square planar structure, which is stabilized by cations, such as K^+ or Na^+ , in the center of the tetrads.^{2–4} Two or more G-quartets are stacked together and interconnected by loops of different length to form a G4.^{5,6}

Aptamers are single-stranded DNA or RNA sequences that can selectively bind to a specific target, including proteins, nucleic acids, cells, tissues and even organisms.^{7–9} Aptamers with affinity for a desired target can be selected through a process called SELEX (Systematic Evolution of Ligands by EXponential enrichment).¹⁰ Previous studies have demonstrated that some aptamers can fold into a G4 structure.¹¹ The

best-known example is the thrombin-binding aptamer (TBA), a 15-mer DNA oligonucleotide with sequence of 5'-GGTTGGTGTGGTTGG-3', which was discovered in 1992 for the recognition of thrombin and is still the best studied anti-thrombin aptamer.¹² This aptamer is capable of inhibiting fibrin clot formation by binding to human thrombin with high selectivity and affinity.^{13–15} Therefore, TBA and its analogs were considered as promising anticoagulant agents and clinical trials have evaluated TBA as an anticoagulant for potential use in acute cardiovascular settings, such as coronary artery bypass graft (CABG) surgery.^{16,17} Due to the potential therapeutic application, many research studies focused on improving its pharmacological properties have been reported in recent years.^{16–18} Simultaneous antidote development is also crucial, as anticoagulant treatment can have side effects such as hemorrhagic complications.^{19,20}

Previous NMR and X-ray structural studies have demonstrated that TBA adopts an antiparallel chair-like G4 structure, which consists of two G-tetrads connected by a TGT loop on one side and two TT loops on the opposite side.^{21–23} Typically, the two TT loops interact with human α -thrombin, which is the binding site of fibrinogen.^{23–27} The G4 structure is of great importance to the function of TBA. Hence, the TBA anticoagulant activity can be inhibited by hybridization with some antidotes, such as a complementary oligonucleotide or small-molecule ligands that can disrupt the conformation of G4.^{13,28} Up to now, only a few TBA

^aMOE Key Laboratory of Bioinorganic and Synthetic Chemistry, School of Chemistry, Sun Yat-sen University, Guangzhou 510275, China. E-mail: cesmzw@mail.sysu.edu.cn; liuwenting@mail.sysu.edu.cn; xiawei5@mail.sysu.edu.cn

^bSchool of Pharmaceutical and Chemical Engineering, Guangdong Pharmaceutical University, Zhongshan 528458, China

^cSchool of Materials Science and Engineering, PCFM Lab, School of Chemistry, Sun Yat-sen University, Guangzhou 510275, China. E-mail: kezhf3@mail.sysu.edu.cn

† Electronic supplementary information (ESI) available: Materials and methods, supporting scheme, figures and tables. See <https://doi.org/10.1039/d2sc01196d>

‡ These authors contributed equally.

G4-binding small molecules have been reported, including TMPyP₄, thioflavin T (ThT) and *N*-methylmesoporphyrin IX (NMM).^{29,30} To recognize and stabilize G4 structures, a series of synthetic small molecules have been identified.^{31–33} In particular, small molecules that have (a) a π -delocalized system, (b) a partial positive charge in the centre of the molecular scaffold, and (c) a positively charged substituent to interact with the grooves, loops, and the negatively charged phosphate backbone prefer to bind to G4 structures.^{33–35} Moreover, small molecule ligands that stabilize the G4 structure could also be applied to regulate or detect intracellular G4 formation.^{36,37} Current structural studies of G4-binding small molecules have mainly focused on compounds with a large planar group, which can form π - π interactions with the guanine plane. Small molecules with non-planar central core structures are rarely studied.

We recently reported an electrically neutral and non-planar platinum compound (Pt1) with a freely rotating *N*-heterocyclic carbene ligand.³⁶ This non-charged and non-planar platinum compound is converted into a positive monovalent planar structure upon binding to VEGF G4. The report highlights the G4 binding activated by adaptive ligand structural transformations and G4 selectivity controlled by binding kinetics, which is a new strategy for G4 selective binding. In this report, we synthesized and characterized an organometallic platinum(II) bis-*N*-heterocyclic carbene compound (*L'*₂LPt, Fig. 1A). FRET and CD thermal melting assays revealed that the melting temperature increase of TBA G4 (Fig. 1B) after *L'*₂LPt binding is clearly higher than that of other G4 DNAs, which is indicative of *L'*₂LPt binding to TBA G4 with a higher affinity. The solution structure of the *L'*₂LPt–TBA G4 complex was determined by NMR spectroscopy. A rotation of the carbene ligand was observed and the cross-shaped *L'*₂LPt molecule bound to antiparallel TBA G4 in a unique half-ligand to half-G-tetrad “wall-mounted” mode with lateral loop interactions. Furthermore, we showed that *L'*₂LPt could abrogate the interaction between the TBA aptamer and thrombin and thereby restore the activity of thrombin.

Results and discussion

Binding of aptamer TBA G4 by *L'*₂LPt

The non-planar platinum compound *L'*₂LPt, which is coordinated by a cyclometalated ligand (L) and two rotated *N*-

heterocyclic carbene ligands (*L'*), was synthesized and characterized (Fig. 1A, Scheme S1, Fig. S1–S3 and Table S1†). FRET and CD melting assays were first applied to investigate the change in *L'*₂LPt-induced thermal stability of various DNA oligonucleotides (Fig. S4 and Table S2†), including three three-G-tetrad telomeric G4s (Tel26,³⁸ wtTel26,³⁹ and wtTel22 (ref. 40)), five three-G-tetrad promoter G4s (c-myc,⁴¹ Bcl2,⁴² P1G4T,⁴² VEGF⁴³ and c-kit87up⁴⁴), two three-G-tetrad intron G4s (MYT1L⁴⁵ and CHL1 (ref. 46)), two two-G-tetrad promoter G4s (c-kit* (ref. 47) and HIV-PRO1 (ref. 48)), one two-G-tetrad aptamer G4 (TBA) and one duplex DNA (F10T). The melting curves and melting temperature change values (ΔT_m) of DNA after the addition of 1.0 equivalent of *L'*₂LPt were recorded (Fig. 2A, S5, and S6, and Tables S3 and S4†).

We found that the stabilization temperatures of DNAs after adding *L'*₂LPt were consistent between the FRET and CD experiments, except for c-kit* G4. The lower FRET ΔT_m of c-kit* G4 is probably related to the labelled fluorophores in the c-kit* DNA sequence, which affect its G4 structure. The results showed that TBA G4 exhibited the largest ΔT_m value (12.4 °C in FRET, 16.4 °C in CD), Tel26, wtTel26, c-kit*, HIV-PRO1 and wtTel22 exhibited moderate ΔT_m values, and other G4s exhibited rather low ΔT_m values. To enable greater comparability, we conducted FRET experiments at different concentrations of K⁺ buffer to make each DNA display similar initial T_m values in the range of 63 ± 2 °C (Fig. S7 and S8, and Tables S5 and S6†). The results of ΔT_m value remained similar. These results indicated that *L'*₂LPt can better stabilize TBA G4 than other G4s. Moreover, the ΔT_m value of duplex DNA was very low (0.0 °C in FRET, 0.2 °C in CD), which is indicative of low affinity and no specific binding of duplex DNA with *L'*₂LPt. By comparing the conformations of the G4s used in these experiments, we found that the G4s with lateral loops are more likely to be stabilized by *L'*₂LPt. In particular, the two-G-tetrad antiparallel G4s with two lateral loops on the same side have much higher ΔT_m values than those of other G4s.

FRET competitive experiments were carried out to explore the selectivity of *L'*₂LPt between TBA and different kinds of DNAs (Fig. S9 and Table S7†). The results showed that after the addition of 50 equivalents of duplex DNA (ds26) and non-lateral-loop G4 DNA (VEGF), the stabilization of *L'*₂LPt to TBA can still be maintained at 75.8% and 58.4%. In contrast, the G4 DNAs with lateral-loops (Tel26 and HIV-PRO1), especially the two-G-tetrad G4 DNA with double lateral-loops (HIV-PRO1), have a significant effect on the interaction of *L'*₂LPt and TBA G4.

To determine the secondary structural transformation and stability of TBA G4 upon *L'*₂LPt binding, CD spectra were acquired for TBA G4 alone or in the presence of different amounts of *L'*₂LPt (Fig. 2B and S10†). The CD spectrum of TBA had two positive bands at 250 and 295 nm, and a negative band at 270 nm, which are characteristic of typical antiparallel G4 folding. No significant change in the CD spectra was observed when the *L'*₂LPt/TBA molar ratio was below 1 : 1. The CD spectrum band intensities at 295 nm and 270 nm slightly decreased with higher concentrations of *L'*₂LPt, suggesting a partial denaturation of TBA. However, the thermal stability of TBA increased when the ratio of *L'*₂LPt/TBA ranged from 0 to 1,




Fig. 1 (A) Schematic diagram of the chemical structure of *L'*₂LPt. (B) The folding topology of TBA G4. Deep red box = (*anti*)-guanine, light red box = (*syn*)-adenine, blue ball = thymine.




Fig. 2 (A) ΔT_m value from FRET and CD melting of different G4s and duplex DNA. FRET data were tested in 0.40 μM DNA interacting with 0.40 μM L₂LPT in 10 mM tris-HCl buffer (pH 7.4) containing 60 mM potassium cacodylate. CD melting data were tested in 3 μM DNA interacting with 3 μM L₂LPT in 10 mM tris-HCl and 100 mM KCl buffer (pH 7.4). (B) CD spectra of L₂LPT titrated into TBA G4 DNA solution at different L₂LPT/TBA ratios. Conditions: pH 7.4, 10 mM tris-HCl, 100 mM KCl solution. (C) Top: ESI-MS titrations of 10 μM TBA with L₂LPT in 150 mM ammonium acetate ($\text{CH}_3\text{CO}_2\text{NH}_4$) buffer (pH 7.4) showing a zoom-in of the 4⁻ charged state. Bottom: Quantification and fitting of the ESI-MS data based on the number of bound ligands (0 L₂LPT and 1 L₂LPT).

and basically remained unchanged at higher ratios. The CD experiment results implied that the stoichiometry of the binding between L₂LPT and TBA G4 is 1 : 1. We also conducted UV-Vis spectroscopy titration experiments (Fig. S11†). With the addition of TBA G4, we observed a slight decrease in the UV/Vis spectrum of L₂LPT at 318 nm.

ESI-MS was used to study the stoichiometries of the complexes and determine their individual K_{app} values.^{49,50} As shown in the results (Fig. 2C and S12†), the ESI-MS spectra exhibited clear ion peaks for free TBA G4 with different electrical charges. After titrating L₂LPT into the TBA G4 solution, clear peaks for the 1 : 1 L₂LPT-TBA G4 complex were observed. We zoomed in on the 4⁻ charged state of the free TBA G4 and the 1 : 1 L₂LPT-TBA G4 complex for the curve fitting procedure. The ESI-MS spectra of TBA and L₂LPT demonstrated that L₂LPT binds TBA G4 and forms a stable 1 : 1 complex with an apparent DNA binding constant (K_{app}) value of $9.30 \times 10^{-6} \text{ mol}^{-1}$.

Moreover, ITC titration was also employed to examine the interactions among the TBA aptamer, L₂LPT and thrombin

(Fig. 3). The combination ratio results verified that both the binding ratios of L₂LPT-TBA and TBA-thrombin were nearly 1.0, and the K_a values of the dual system with L₂LPT-TBA and TBA-thrombin were $1.83 \times 10^7 \text{ mol}^{-1}$ and $8.46 \times 10^6 \text{ mol}^{-1}$, respectively. We then added L₂LPT to the TBA-thrombin complex and set $N = 1$ and $K_{a-\text{Pt}} = 1.83 \times 10^7 \text{ mol}^{-1}$. The result of $K_{a-\text{TBA}} = 6.75 \times 10^5 \text{ mol}^{-1}$ is much lower than its original intrinsic affinity. Therefore, L₂LPT can competitively bind TBA G4 against the TBA/thrombin system. The difference in enthalpy changes between the binary system and ternary system indicated that L₂LPT caused a thermodynamic change after addition to the TBA/thrombin complex. These results indicate that L₂LPT could compete with thrombin for the binding of TBA G4.

NMR studies of L₂LPT interaction with TBA G4

Subsequently, to further explore the binding mechanism, the interaction between the organometallic compound L₂LPT and TBA G4 was analysed by NMR spectroscopy under




Fig. 3 ITC data and fitting curves of different titrations of L'_2LPt , TBA and thrombin at a cell concentration of $6 \mu M$ interacting with a $100 \mu M$ syringe in PBS buffer (pH 7.4) at $25^\circ C$.

physiologically relevant K^+ conditions. 1D 1H NMR titration experiments were then executed (Fig. 4A). In the 1D NMR spectra, eight imino signals were observed for free TBA G4 and the signals were assigned (labelled in black) based on the reported TBA G4 structure.²¹ As L'_2LPt was titrated into the TBA sample, the chemical shifts of TBA G4 imino protons gradually changed and a new set of distinct imino proton peaks (labelled in blue) appeared until the L'_2LPt /TBA ratio reached 1 : 1. Even after adding more equivalents of L'_2LPt compound at L'_2LPt /TBA ratios of 2 : 1 and 3 : 1, the spectra retained the same

pattern as for the 1 : 1 ratio. The results indicate that L'_2LPt binds TBA G4 and can form a 1 : 1 stable complex, which is consistent with the ESI-MS data (Fig. 2C and S12[†]).

As the well-resolved 1D NMR spectra indicated that the L'_2LPt -TBA G4 complex was suitable for high resolution structural analysis, we decided to solve the solution structure of the complex to understand how L'_2LPt interacts with TBA G4. A full set of 2D-NOESY, TOCSY and COSY NMR data on the 1 : 1 L'_2LPt -TBA complex were recorded in 25 mM K-phosphate and 70 mM KCl buffer supplemented with 10% D_2O (Fig. 4B and




Fig. 4 (A) Imino proton regions of the 1D 1H NMR titration spectra of TBA interacting with L'_2LPt . The imino proton assignments are labeled. (B) The $H1'$ - $H6/H8$ region of the 2D NOESY spectrum of the TBA G4 bound to 1.0 equivalents of L'_2LPt . The complete sequential assignment pathway is shown. Residues with *syn* glycosidic conformations are marked in black, and those with *anti* glycosidic conformations are marked in blue. (C) The chemical shift difference of TBA G4 protons between the free TBA and the 1 : 1 L'_2LPt -TBA complex. Conditions: 25 mM K-phosphate, 70 mM KCl solution, pH 7.0, $25^\circ C$.

S13–S16†). The proton assignments of the H1s and H8/H6s of the free and bound TBA G4 were based on the previously reported NMR structure of TBA G4,²¹ as displayed by the H1'–H6/H8 (Fig. S13†) and H1–H6/H8/H1'/Me (Fig. S16†) regions. We completely assigned all of the protons of TBA G4 by assigning H1s and H8/H6s, followed by the sequential connectivity of H8/H6-sugar protons and the sequential assignment method (Tables S8 and S9†). The protons of bound L₂LPT were assigned using TOCSY (Fig. S14†) and NOESY spectra.

Similar to the free TBA G4, the G1, G5, G10, and G14 residues adopted a *syn* glycosidic conformation, which was reflected by the high intensities of the H1'–H8 NOE cross-peaks (Fig. S17†). Moreover, the 1 : 1 bound TBA G4 retained the same antiparallel folding as indicated by the similar characteristic guanine H1–H8 proton connectivity patterns of the free TBA G4 (Fig. S16†). Based on the complete NMR assignments, the proton chemical shift differences between the free TBA G4 and the 1 : 1 L₂LPT–TBA G4 complex were calculated (Fig. 4C). Significant proton chemical shift changes were found for the T4, G5, G11, T12 and T13 residues, illustrating that these residues are involved in L₂LPT binding and that large conformational changes of the T4 and T12–T13 loop regions are induced. The intermolecular NOE cross-peaks between L₂LPT and TBA G4 were observed and summarized (Tables S10 and S11†), revealing specific binding of L₂LPT with TBA G4.

Solution structure of the 1 : 1 L₂LPT–TBA G4 complex

We calculated the solution structure of the 1 : 1 L₂LPT–TBA complex using NMR NOE restraints (Table S12†). The ensemble

of the 10 lowest-energy structures is presented in stereo view (Fig. 5A). A representative structure is also shown (Fig. 5B). Both the L₂LPT compound and TBA G4 undergo large structural changes to form a stable complex structure.

As shown in the complex (Fig. 5B), the L₂LPT compound adopts a non-planar cross-shape conformation. The carbene ligand L'-1 of L₂LPT rotates to form a plane with the cyclometalated ligand L (Fig. 5C). This cyclometalated-carbene ligand plane is embedded and stacks on G5 and G11, covering half of the external G-tetrad of TBA G4 (Fig. 5C), which is further covered by the lateral T4, T12 and T13 residues (Fig. 5D and E). In particular, the cyclometalated ligand L of L₂LPT stacks over G5, whereas the rotated carbene ligand L'-1 of L₂LPT stacks over the G11 residue with the pyridine of the carbene ligand tilting. It is notable that the heavy atom Pt stays out of the G-tetrad, which is disadvantageous for ligand binding. Intriguingly, the other carbene ligand L'-2 is relatively perpendicular to the L–L'-1 plane and stretches along the G4 groove forming a hydrogen bond between the N atom of pyridine and the NH₂ group of G11 in the external G-tetrad (Fig. 5F), which anchors the L₂LPT position to achieve strong binding to G4. Therefore, the cross-shape organometallic compound L₂LPT adaptively adopts an unusual half-ligand to half-G-tetrad “wall-mounted” mode bound to antiparallel TBA G4 through both π -stacking and hydrogen bonding with the same G-tetrad.

The lateral loops T12–T13 and T3–T4 of TBA G4 also display important conformational changes induced by L₂LPT binding. In the NMR structure of free TBA G4 (ref. 21) (Fig. 6A), the T4 and T13 residues form hydrogen bonded T4–T13 base pair




Fig. 5 (A) The ensemble of the superimposed 10 NMR restraint-refined structures of the 1 : 1 L₂LPT–TBA complex in the stereo view (PDB ID 7V3T). (B) A representative structure of the 1 : 1 complex shown in stereo view. (C–E) Different views of the L₂LPT-induced binding pockets. (F) Potential hydrogen bonding between the L₂LPT carbene ligand L'-2 and G11 of TBA G4. The distance between the N atom on the pyridine of the carbene ligand L'-2 and the H atom on the NH₂ of the G11 base is 2.0 Å.






Fig. 6 (A) Overlapping structures of free TBA G4 (PDB ID 148D) and 1 : 1 L'2LPT-TBA G4 complex (PDB ID 7V3T) showing the structural changes of TBA G4. (B) Overlapping structures of free and bound L'2LPT showing structural changes upon TBA G4 binding.

stacks on top of the G-tetrad and the T3 and T12 residues are more dynamic in conformation. Upon binding to L'2LPT, the T4-T13 base pair is destroyed and the lateral TT loops are re-oriented to form a new binding pocket. In the complex structure (Fig. 5D and E), the T12-T13 residues cover and stack with the carbene ligand L'-1 and the T4 residue stacks on the cyclometalated ligand L to stabilize the entire L'2LPT-TBA G4 complex structure, whereas the T3 residue is flexible toward the outside of the G-tetrad.

"Wall-mounted" binding mode of L'2LPT to antiparallel TBA G4

In the 1 : 1 L'2LPT-TBA complex structure, the orientation and position of the L'2LPT compound is well defined. The L'2LPT molecule is coordinated by a cyclometalated ligand and two carbene ligands. This two carbene ligands can be rotated, which is quite different from the unchanged or slightly changed small molecules in most previous reports.⁵¹⁻⁵³ Through structure calculation and optimization, the L'2LPT compound was found to have a non-planar structure (Fig. 6B), which is not a traditional ligand conformation for strong G4 binding. However, L'2LPT adjusts to a cross-shape conformation to bind TBA G4 and form a well-defined complex structure. This conformational adjustment upon G4 binding is significant for specific G4 interactions.

It is worth noting that TBA has an approximate 2-fold symmetry coincident with the helix axis apart from the TGT loop. Because the TGT loop does not interact with L'2LPT, it seems that two practically equivalent binding modes of the

ligand to TBA are possible. However, in the free TBA G4 solution structure, the conformations of these two binding sites are different, which results in a large difference in the binding affinity. In the solution structure of TBA,²¹ the two TT loops (T3-T4, T12-T13) are not in the same conformation (Fig. S18A and B†). T4 and T13 are well-defined and stacked on the G2-G5-G11-G14 G-tetrad, and T3 is on top of G2 and T4, whereas T12 shows much flexibility. From the top view (Fig. S18B†), we see that the G2-G14 side is more buried and covered by T3, T12 and T13. In contrast, the G5-G11 side is exposed, so L'2LPT has greater potential for interacting and stacking with G5 and G11 (Fig. S18C and D†). Moreover, the TGT loop is on the G5-G11 side. Because of the topological and steric effect of the TGT loop, the groove on the G5-G11 side is wider than that on the G2-G14 side (Fig. S18B†). As a result, the G5-G11 side has a wider groove to accommodate the L'2LPT ligand and is more exposed, which creates a higher affinity for ligand binding than the G2-G14 side. Importantly, after binding one L'2LPT compound, it is difficult to bind another L'2LPT compound on the G2-G14 side because of steric hindrance by the G2-G5-G11-G14 G-tetrad. Consequently, we found one strong binding and obtained only one stable L'2LPT-TBA solution structure.

This is the first solution structure of small molecules binding to antiparallel DNA G4 with two G-tetrad layers. In particular, the NMR solution structure revealed that L'2LPT binds to antiparallel TBA in a very unique half-ligand to half-G-tetrad "wall-mounted" binding mode, which is significantly different from the previously reported π -delocalized molecules. The half-G-tetrad binding structure is reported in the solution

structure of a 2 : 1 quindoline-c-MYC complex.⁴¹ The quindolines are stacked with two of the four guanines from each external tetrad with crescent-shaped cyclic fused rings. However, L₂LPT interacted with two guanines with its two separated ligands, *i.e.* the cyclometalated ligand and carbene ligand stacked with G5 and G11 residues respectively in the external G-tetrad.

The common strategy for targeting G4 is to design small molecules with a planar aromatic central core. From the obtained complex structure, we found that non-planar small molecules could also bind G4 in an induced-fit manner through a “wall-mounted” binding mode, different from most G4 ligands. Previous reports have shown a similar “wall-mounted” binding mode that is formed by the interactions of the ruthenium polypyridyl compounds with telomeric G4s in two crystal structures.^{55,56} Both reports utilize a large planar automatic ligand to bind to the G-tetrad *via* π - π stacking, whereas other ligands and metallic ruthenium centers are positioned on the G4 groove, without hydrogen bonding. No structural changes of these ruthenium compounds were observed. The ruthenium centers are also outside of the G-tetrad, similar to our “wall-mounted” mode. Thus, in future development, we believe that the non-planar small molecules will provide a complementary design principle for compounds targeting G4 or similar biomolecules, and the “wall-mounted” mode could be a possible interaction for these ligands and G4s.

Competitive binding of the platinum compound and thrombin to the TBA aptamer

TBA G4 is a potent inhibitor of thrombin, and it has been reported that the anti-thrombin effects of aptamers can be antagonized.⁵⁴ We then preliminarily explored the effects of L₂LPT-binding on the inhibitory activity of TBA G4 against thrombin.

As thrombin could induce fibrinogen to coagulate, we conducted a fibrinogen clotting assay using a thrombin, TBA and L₂LPT ternary system (Fig. 7 and Table S13†). As shown in the results, the fibrinogen clotting time is approximately 15 s in the system with only thrombin. The clotting time substantially increased to 52.7 $\pm$ 2.3 s, 97.4 $\pm$ 2.4 s and 133.8 $\pm$ 3.1 s when adding 200, 500, and 1000 nM TBA, respectively, which is indicative of the inhibition of thrombin activity by TBA G4. After incubation with L₂LPT, the fibrinogen clotting time was significantly reduced, implying that the recovery of thrombin activity was influenced by L₂LPT. Typically, the reduction in fibrinogen clotting time is correlated with the increasing amount of L₂LPT. Under incubation with a 3.0 L₂LPT/TBA ratio of L₂LPT, the thrombin clotting time decreased to 29.3 $\pm$ 0.9 s, 38.8 $\pm$ 3.0 s and 55.6 $\pm$ 3.9 s respectively, which indicated that the thrombin activity recovered by almost 50%. We also used two typical G4 binders TMPyP₄ and PDS as control in this experiment. The result showed that the TMPyP₄ had less effect on clotting time than PDS and the recovery of coagulation time of both TMPyP₄ and PDS is weaker than L₂LPT. This may be due to the fact that these two typical G4 binders interact with the G-tetrad plane and have fewer interactions with the TT loop




Fig. 7 Fibrinogen clotting time of thrombin alone (1.0 ml of PBS containing 2.0 mg ml⁻¹ of fibrinogen added to 100 μ l/10 NIH per ml of human thrombin) or in the presence of 0, 200, 500 and 1000 nM concentrations of TBA and different equivalents of L₂LPT. TMPyP₄ and PDS were used as positive control. The bars of the control and vehicle represent the fibrinogen clotting time values of the system in the absence of any L₂LPT/TBA and diluted with the buffer alone, respectively.

structure of TBA, which is the binding site of TBA and thrombin. These data clearly demonstrated that L₂LPT-binding abrogates the thrombin-TBA interaction and releases TBA-inactivated thrombin.

Conclusion

In this study, we identified a quasi-cross-shaped Pt compound, L₂LPT, with a non-planar central core, which has a strong affinity for the DNA G4 aptamer TBA. The identification and characterization of this new half-ligand to half-G-tetrad “wall-mounted” binding mode between the small non-planar molecule L₂LPT and the antiparallel TBA G4 are of great importance. Currently, the structure-based design of small molecules interacting with unimolecular G4 is focused on the development of ligands with planar cyclic fused rings that interact with the external G-tetrads. Here we found that the non-planar small molecules could also bind G4 with high selectivity. The obtained L₂LPT-TBA complex structure is not only the first solution complex structure of a small molecule bound to intramolecular antiparallel G4 through both π -stacking and hydrogen bonding within a G-tetrad, but also provides a new paradigm for designing G4-specific targeting non-planar small molecules.

Data availability

Experimental data associated with the article can be found in the ESI.† The coordinates for the structure of the 1 : 1 L₂LPT-TBA G4 complex (accession code 7V3T) have been deposited in the Protein Data Bank.



Author contributions

Z.-W. M. and W. L. conceived and directed the project. J. H. and B.-B. L. designed, synthesized and characterized the L₂LPT compound. H.-G. Y. analyzed the crystal structure of L₂LPT. B.-C. Z. and X.-Y. X. performed FRET, CD, ESI-MS, and NMR experiments, fibrinogen clotting and assigned NMR spectra. W. L., L.-Y. L. and J. J. did structure refinements. B.-C. Z. wrote the paper with the help of Z.-W. M., W. L., X. W. and Z. K.

Conflicts of interest

The authors declare no conflict of interest.

Acknowledgements

This work was funded by the National Natural Science Foundation of China (No. 21837006, 22007103, 91953117, 21572282), the Ministry of Education of China (IRT-17R111), and Science and Technology Planning Project of Guangdong Province (No. 207999 and 2020A1515011439). We thank Dr Zhihui Xiao and Dr Xiaohong Zheng (Equipment Public Service Center, South China Sea Institute of Oceanology, Chinese Academy of Sciences) for their support with the NMR experiments.

Notes and references

- M. Gellert, M. N. Lipsett and D. R. Davies, *Proc. Natl. Acad. Sci., USA*, 1962, **48**, 2013–2018.
- J. Zhou, S. Amrane, F. Rosu, G. F. Salgado, Y. Bian, H. Tateishi-Karimata, E. Largy, D. N. Korkut, A. Bourdoncle, D. Miyoshi, J. Zhang, H. Ju, W. Wang, N. Sugimoto, V. Gabelica and J.-L. Mergny, *J. Am. Chem. Soc.*, 2017, **139**, 7768–7779.
- D. Varshney, J. Spiegel, K. Zyner, D. Tannahill and S. Balasubramanian, *Nat. Rev. Mol. Cell Biol.*, 2020, **21**, 459–474.
- L. Stefan and D. Monchaud, *Nat. Rev. Chem.*, 2019, **3**, 650–668.
- M. Marušič, P. Šket, L. Bauer, V. Viglasky and J. Plavec, *Nucleic Acids Res.*, 2012, **40**, 6946–6956.
- J. Spiegel, S. Adhikari and S. Balasubramanian, *Trends Chem.*, 2020, **2**, 123–136.
- A. D. Ellington and J. W. Szostak, *Nature*, 1990, **346**, 818–822.
- P. Röthlisberger and M. Hollenstein, *Adv. Drug Deliv. Rev.*, 2018, **134**, 3–21.
- A. B. Iliuk, L. Hu and W. A. Tao, *Anal. Chem.*, 2011, **83**, 4440–4452.
- Y. X. Wu and Y. J. Kwon, *Methods*, 2016, **106**, 21–28.
- G. W. Collie and G. N. Parkinson, *Chem. Soc. Rev.*, 2011, **40**, 5867–5892.
- L. C. Bock, L. C. Griffin, J. A. Latham, E. H. Vermaas and J. J. Toole, *Nature*, 1992, **355**, 564–566.
- C. Riccardi, E. Napolitano, C. Platella, D. Musumeci and D. Montesarchio, *Pharmacol. Therapeut.*, 2021, **217**, 107649.
- B. Deng, Y. Lin, C. Wang, F. Li, Z. Wang, H. Zhang, X.-F. Li and X. C. Le, *Anal. Chim. Acta*, 2014, **837**, 1–15.
- R. F. Macaya, P. Schultze, F. W. Smith, J. A. Roe and J. Feigon, *Proc. Natl. Acad. Sci., USA*, 1993, **90**, 3745–3749.
- A. Virgilio, L. Petraccone, V. Vellecco, M. Bucci, M. Varra, C. Irace, R. Santamaria, A. Pepe, L. Mayol, V. Esposito and A. Galeone, *Nucleic Acids Res.*, 2015, **43**, 10602–10611.
- L. Martino, A. Virno, A. Randazzo, A. Virgilio, V. Esposito, C. Giancola, M. Bucci, G. Cirino and L. Mayol, *Nucleic Acids Res.*, 2006, **34**, 6653–6662.
- I. Russo Krauss, V. Spiridonova, A. Pica, V. Napolitano and F. Sica, *Nucleic Acids Res.*, 2016, **44**, 3969.
- H.-L. Bao, T. Ishizuka, A. Yamashita, E. Furukoji, Y. Asada and Y. Xu, *J. Med. Chem.*, 2021, **64**, 711–718.
- M. Mahmoud, C. Ruppert, S. Rentschler, S. Laufer and H.-P. Deigner, *Sens. Actuators, B*, 2021, **333**, 129246.
- P. Schultze, R. F. Macaya and J. Feigon, *J. Mol. Biol.*, 1994, **235**, 1532–1547.
- J. A. Kelly, J. Feigon and T. O. Yeates, *J. Mol. Biol.*, 1996, **256**, 417–422.
- I. Russo Krauss, A. Merlino, A. Randazzo, E. Novellino, L. Mazzarella and F. Sica, *Nucleic Acids Res.*, 2012, **40**, 8119–8128.
- I. Russo Krauss, A. Merlino, C. Giancola, A. Randazzo, L. Mazzarella and F. Sica, *Nucleic Acids Res.*, 2011, **39**, 7858–7867.
- A. Pica, I. Russo Krauss, A. Merlino, S. Nagatoishi, N. Sugimoto and F. Sica, *FEBS J.*, 2013, **280**, 6581–6588.
- R. Dolot, C. H. Lam, M. Sierant, Q. Zhao, F.-W. Liu, B. Nawrot, M. Egli and X. Yang, *Nucleic Acids Res.*, 2018, **46**, 4819–4830.
- I. Smirnov, N. Kolganova, R. Troisi, F. Sica and E. Timofeev, *Mol. Ther.–Nucleic Acids*, 2021, **23**, 863–871.
- C. Roxo, W. Kotkowiak and A. Pasternak, *Molecules*, 2019, **24**, 3781.
- A. Joachimi, G. Mayer and J. S. Hartig, *J. Am. Chem. Soc.*, 2007, **129**, 3036–3037.
- D. Zhao, X. Dong, N. Jiang, D. Zhang and C. Liu, *Nucleic Acids Res.*, 2014, **42**, 11612–11621.
- R. Vilar, *Metal ions in life sciences*, 2018, vol. 18.
- Q. Cao, Y. Li, E. Freisinger, P. Z. Qin, R. K. O. Sigel and Z.-W. Mao, *Inorg. Chem. Front.*, 2017, **4**, 10–32.
- E. Ruggiero and S. N. Richter, *Nucleic Acids Res.*, 2018, **46**, 3270–3283.
- S. Neidle, *J. Med. Chem.*, 2016, **59**, 5987–6011.
- S. Neidle, *Nat. Rev. Chem.*, 2017, **1**, 0041.
- B.-C. Zhu, J. He, W. Liu, X.-Y. Xia, L.-Y. Liu, B.-B. Liang, H.-G. Yao, B. Liu, L.-N. Ji and Z.-W. Mao, *Angew. Chem., Int. Ed.*, 2021, **60**, 15340–15343.
- D. R. Calabrese, X. Chen, E. C. Leon, S. M. Gaikwad, Z. Phyto, W. M. Hewitt, S. Alden, T. A. Hilimire, F. He, A. M. Michalowski, J. K. Simmons, L. B. Saunders, S. Zhang, D. Connors, K. J. Walters, B. A. Mock and J. S. Schneekloth, *Nat. Commun.*, 2018, **9**, 4229.
- J. Dai, C. Punchihewa, A. Ambrus, D. Chen, R. A. Jones and D. Yang, *Nucleic Acids Res.*, 2007, **35**, 2440–2450.



- 39 J. Dai, M. Carver, C. Punchihewa, R. A. Jones and D. Yang, *Nucleic Acids Res.*, 2007, **35**, 4927–4940.
- 40 Y. Wang and D. J. Patel, *Structure*, 1993, **1**, 263–282.
- 41 J. Dai, M. Carver, L. H. Hurley and D. Yang, *J. Am. Chem. Soc.*, 2011, **133**, 17673–17680.
- 42 B. Onel, M. Carver, G. Wu, D. Timonina, S. Kalarn, M. Larriva and D. Yang, *J. Am. Chem. Soc.*, 2016, **138**, 2563–2570.
- 43 P. Agrawal, E. Hatzakis, K. Guo, M. Carver and D. Yang, *Nucleic Acids Res.*, 2013, **41**, 10584–10592.
- 44 A. T. Phan, V. Kuryavyi, S. Burge, S. Neidle and D. J. Patel, *J. Am. Chem. Soc.*, 2007, **129**, 4386–4392.
- 45 K. W. Lim, P. Jenjaroenpun, Z. J. Low, Z. J. Khong, Y. S. Ng, V. A. Kuznetsov and A. T. Phan, *Nucleic Acids Res.*, 2015, **43**, 5630–5646.
- 46 V. Kuryavyi and D. J. Patel, *Structure*, 2010, **18**, 73–82.
- 47 A. Kotar, R. Rigo, C. Sissi and J. Plavec, *Nucleic Acids Res.*, 2018, **47**, 2641–2653.
- 48 S. Amrane, A. Kerkour, A. Bedrat, B. Vialet, M.-L. Andreola and J.-L. Mergny, *J. Am. Chem. Soc.*, 2014, **136**, 5249–5252.
- 49 G. Yuan, Q. Zhang, J. Zhou and H. Li, *Mass Spectrom. Rev.*, 2011, **30**, 1121–1142.
- 50 A. Marchand, D. Strzelecka and V. Gabelica, *Chem.–Eur. J.*, 2016, **22**, 9551–9555.
- 51 A. T. Phan, V. Kuryavyi, H. Y. Gaw and D. J. Patel, *Nat. Chem. Biol.*, 2005, **1**, 167–173.
- 52 W. Liu, Y.-F. Zhong, L.-Y. Liu, C.-T. Shen, W. Zeng, F. Wang, D. Yang and Z.-W. Mao, *Nat. Commun.*, 2018, **9**, 3496.
- 53 L.-Y. Liu, W. Liu, K.-N. Wang, B.-C. Zhu, X.-Y. Xia, L.-N. Ji and Z.-W. Mao, *Angew. Chem., Int. Ed.*, 2020, **59**, 9719–9726.
- 54 M. Kovačič, P. Podbevšek, H. Tateishi-Karimata, S. Takahashi, N. Sugimoto and J. Plavec, *Nucleic Acids Res.*, 2020, **48**, 3975–3986.
- 55 K. McQuaid, H. Abell, S. P. Gurung, D. R. Allan, G. Winter, T. Sorensen, D. J. Cardin, J. A. Brazier, C. J. Cardin and J. P. Hall, *Angew. Chem., Int. Ed.*, 2019, **58**, 9881–9885.
- 56 K. T. McQuaid, S. Takahashi, L. Baumgaertner, D. J. Cardin, N. G. Paterson, J. P. Hall, N. Sugimoto and C. J. Cardin, *J. Am. Chem. Soc.*, 2022, **144**, 5956–5964.

